Insider buying last 90 days
No open-market insider purchases were filed for ABT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ABT insider filing, plotted on the chart in Gekko.Open ABT in Gekko
NYSE: ABT
Abbott Laboratories (ABT) Stock Analysis & Forecast
Nov 4 close
$115.51+6.11 (+5.6%)
Gekko Brief
AI summaryNov 4 closeAbbott's week is dominated by a mix of quarterly results and a cluster of cardiovascular device news. Third-quarter net sales rose 14.5% to $13.013 billion, helped by the Exact Sciences acquisition and growth in Medical Devices and Established Pharmaceutical Products, while net earnings fell to $920 million from $1.644 billion a year earlier. Separately, Abbott presented positive one-year VERITAS trial data for its Amulet 360 left atrial appendage occluder, showing 96.3% complete closure and a 1.8% rate of ischemic stroke or systemic embolism, alongside TECTONIC trial results supporting its SonicForce IVL system and the start of a pivotal trial for its Cephea mitral valve device. Abbott also faces a product liability lawsuit tied to its Proclaim Spinal Cord Stimulator System and is navigating Medicare coverage changes for continuous glucose monitors alongside Dexcom.
Shares closed at $115.51, up 5.6%, sitting above both the 50-day average of $104.05 and the 200-day average of $101.54. The stock is in the GekkoIndex Distribution zone with a score of 43.6, while trading about 8% below the Gekko Fair Value of $125.56.
The next earnings date falls on 28 January 2027, outside a typical 20-trading-day window. Congress shows 2 buys and 0 sells over the last 90 days, and seasonality over the next 20 trading days has averaged 3.3% across 5 years, rising in 3 of them. Analyst consensus among 19 firms stands at 17 buy and 2 hold ratings, with a consensus target of $118.52.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Abbott Laboratories price vs fair value
Close $115.51200-day averageGekko Fair Value $125.56
Abbott Laboratories quick facts
- Market cap
- $199.9B
- P/E ratio
- 41
- Forward P/E
- 17.9
- EPS, TTM
- $2.69
- Revenue, TTM
- $48.23B
- Profit margin
- 9.8%
- Dividend yield
- 2.37%
- Beta
- 0.54
- Volume
- 12.71M avg 9.67M
- 1-year return
- −6.7%
- Typical daily move
- ±2.9%
- Typical 20-day move
- ±4.4%
- 50-day average
- $104.05
- 200-day average
- $101.54
- Next earnings
- Jan 28 before open
- Shares outstanding
- 1.73B
Abbott Laboratories swing-trade checklist
Abbott Laboratories scores 5 supportive, 0 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive0 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $115.51 is above the 50-day ($104.05) and 200-day ($101.54) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
43.6, Distribution
Reading 43.6 is in the Distribution zone.
See the GekkoIndex - Fair valuesupportive
8.0% below
Price is 8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 2 buys / 0 sales.
See smart money - Earnings risksupportive
Reports in 84 days
Next report Jan 28, 2027, 84 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+3.3% on average
From this point in the calendar, the next 20 trading days averaged +3.3% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Abbott Laboratories stock chart and price history
Abbott Laboratories closed at $115.51 on Nov 4, 2026, −6.7% over the past year, inside a 52-week range of $81.97 to $132.03.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +17.7%
- 3 months
- +7.0%
- 6 months
- +33.8%
- 1 year
- −6.7%
The full ABT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ABT in Gekko
Follow Abbott Laboratories through every session
Put ABT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ABT in GekkoFree for 7 days. No credit card required.
About Abbott Laboratories
Abbott Laboratories works across healthcare, researching, making and distributing a broad range of health products worldwide through its own operations and related entities. It is organized into four areas: established pharmaceuticals, diagnostics, nutrition and medical devices. Its pharmaceutical line includes generic medicines for conditions such as digestive disorders, hormone-related issues, cholesterol and blood pressure management, thyroid problems, vertigo, pain and migraine, along with an anti-infective, flu vaccines and treatments that support colon function.
The diagnostics business supplies laboratory systems for immunoassay, chemistry, hematology and transfusion testing, along with molecular platforms that process DNA and RNA and identify infectious agents. It also makes point-of-care devices, testing cartridges, rapid tests for pathogens including HIV, SARS-CoV-2, influenza and RSV, plus tools for cardiometabolic and substance testing, remote monitoring, consumer self-tests and lab automation software. The nutrition segment produces formulas for infants and adults, while the medical devices unit makes cardiovascular products such as rhythm management and structural heart devices, along with diabetes care tools and neuromodulation devices for pain and movement disorders.
Abbott Laboratories was founded in 1888 and is headquartered in North Chicago, Illinois. Its shares are listed on the NYSE under the ticker ABT.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- abbott.com
Abbott Laboratories GekkoIndex: the smart money zone
Abbott Laboratories’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 43.6, in the Distribution zone, down 14.2 points over five sessions.
43.6Distribution
Down 14.2 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 32 | 0.0% | −1.5% | ||
| Accumulation | 268 | +0.1% | +0.3% | ||
| Neutral | 366 | 0.0% | −0.2% | ||
| Distribution (current zone) | 26 | −0.2% | −0.3% | ||
| Selling | 5 | Too few readings yet | |||
Average ABT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the ABT price, zone by zone.Track ABT in Gekko
Is Abbott Laboratories stock overvalued? Gekko Fair Value
Abbott Laboratories trades 8.0% below Gekko Fair Value of $125.56, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Abbott Laboratories shares are worth, recalculated every trading day.
$125.56
Gekko Fair Value, Nov 4, 2026
8.0% Undervalued
At the end of Aug 2026 the price was 12.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ABT in Gekko
Abbott Laboratories insider and Congress trading
No open-market insider purchases were filed for Abbott Laboratories, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
2trades disclosed: 2 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Oct 12 traded Sep 18 |
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Abbott Laboratories has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.05B
- As a share of market cap
- 0.52%
- Trailing four quarters
- $1.83B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds ABT.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Abbott Laboratories earnings: next date and track record
Abbott Laboratories reports on Jan 28, 2027, before the open (84 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Jan 28, 2027
Expected before the open, 84 days away
- EPS estimate
- $1.64
- Revenue estimate
- $13.22B
3 of 8reports beat the EPS estimate
±6%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 21, 2026 AI summary
- What they said
- Abbott announced Q3 2026 results alongside a major strategic initiative to spin off its nutrition business into an independent publicly traded company. The nutrition segment generates approximately $8.5 billion in annual sales with 16,000 employees across 14 manufacturing sites, housing brands including Similac, Ensure, Glucerna, and Pedialyte. Management cited evolving consumer-driven market dynamics as justification for the separation, believing both entities will achieve greater value independently. Daniel Salvadori will lead the new nutrition company as CEO.
- Guidance
- No specific financial guidance or revenue/earnings targets were provided in this excerpt. Management expects the new nutrition company to qualify for S&P 500 inclusion based on its scale and financial profile. Further details on separation timeline and financial targets are anticipated.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 21, 2026 | $1.42 est $1.42 | $13.01B est $12.99B | +0.1% |
| Jul 16, 2026 | $1.31 est $1.28 | $12.59B est $12.52B | +12.8% |
| Apr 16, 2026 | $1.15 est $1.15 | — | −4.7% |
| Jan 22, 2026 | $1.50 est $1.49 | $11.46B est $11.80B | −11.0% |
| Oct 15, 2025 | $1.30 est $1.30 | $11.37B est $11.39B | −4.2% |
| Jul 17, 2025 | $1.26 est $1.26 | $11.14B est $11.09B | −6.1% |
| Apr 16, 2025 | $1.09 est $1.07 | $10.36B est $10.41B | +3.8% |
| Jan 22, 2025 | $1.34 est $1.34 | $10.97B est $11.03B | +5.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Abbott Laboratories stock forecast and analyst price targets
Analysts’ average 12-month price target for Abbott Laboratories is $118.52, +2.6% from the last close, from 19 firms rating the stock in the last 90 days.
$118.52consensus 12-month target, +2.6% from the last close
Now $115.51Avg $118.52
Low $115High $135
Each firm’s latest rating in the last 90 days: 19 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Piper Sandler | $118 | +2.2% |
| Oct 30 | Bank of America Securities | $115 | −0.4% |
| Oct 27 | Argus Research | — | — |
| Oct 23 | Wells Fargo | $120 | +3.9% |
| Oct 23 | Evercore ISI | $120 | +3.9% |
−0.3%average 20-day move after past Distribution readings
+3.3%average move over the next 20 trading days in the last 5 years
±2.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Abbott Laboratories seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Abbott Laboratories averaged +3.3% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.6% | 2 of 5 |
| Next 10 trading days | +2.4% | 3 of 5 |
| Next 15 trading days | +2.9% | 4 of 5 |
| Next 20 trading days | +3.3% | 3 of 5 |
| Next 30 trading days | +4.9% | 4 of 5 |
For scale, ABT’s typical 20-trading-day move in either direction is about 4.4%.
Abbott Laboratories market cap and key statistics
Abbott Laboratories’s market cap is $199.9B, with a P/E ratio of 41 and revenue of $48.23B over the last twelve months.
Valuation
- Market cap
- $199.9B
- P/E ratio
- 41
- Forward P/E
- 17.9
- EPS, TTM
- $2.69
- Gekko Fair Value
- $125.56
Trading
- Volume
- 12.71M
- Avg volume, 20 days
- 9.67M
- 52-week high
- $132.03
- 52-week low
- $81.97
- Shares outstanding
- 1.73B
Financials
- Revenue, TTM
- $48.23B
- Profit margin
- 9.8%
- Return on equity
- 10.6%
- Quarterly earnings growth, YoY
- −43.7%
Risk and income
- Beta
- 0.54
- Typical daily move
- ±2.9%
- Typical 20-day move
- ±4.4%
- Dividend yield
- 2.37%
Abbott Laboratories stock news this week
Coverage of Abbott Laboratories this week reads positive: 10 positive, 4 neutral and 4 negative headlines.
- Sales rise 14.5% at Abbott (ABT), but Q3 earnings fall.Stock Titan, Nov 4
- Abbott Laboratories (ABT) Reported Strong One Year Amulet 360 Trial ResultsSimply Wall St, Nov 4
- 99,391 Shares of Abbott Laboratories $ABT Bought by Associated Banc CorpDefense World, Nov 4
- TCT 2026: Abbott’s Amulet 360 Hits 96.3% Complete LAA Closure at One Year in Pivotal VERITAS StudyMedtech Insight, Nov 4
- TCT 2026: Abbott Expects H1 2027 FDA Approval Of SonicForce IVL After Successful TECTONIC TrialMedtech Insight, Nov 3
- Abbott Laboratories $ABT Stock: Heritage Investors Management Corp Trims HoldingsDefense World, Nov 3
Abbott Laboratories peers
Abbott Laboratories’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 14.5% above |
| ISRGIntuitive Surgical | Distribution | 30.4% above |
| DHRDanaher | Neutral | 3.6% above |
| MDTMedtronic | Neutral | 16.0% below |
| SYKStryker | Distribution | 6.5% above |
| BSXBoston Scientific | Neutral | 26.8% below |
A peer links to its own page where one exists.
Abbott Laboratories stock FAQ
What is Abbott Laboratories’s market cap?
Abbott Laboratories’s market cap is $199.9B at the Nov 4, 2026 close of $115.51, with 1.73B shares outstanding. The shares trade on a P/E ratio of 41.
What is the Abbott Laboratories stock forecast?
The consensus analyst 12-month price target for Abbott Laboratories is $118.52, +2.6% from the last close. Of the 19 firms that rated the stock in the last 90 days, 17 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Abbott Laboratories stock overvalued or undervalued?
On Gekko’s estimate Abbott Laboratories is undervalued: the Nov 4, 2026 close of $115.51 is 8.0% below Gekko Fair Value of $125.56. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Abbott Laboratories report earnings next?
Abbott Laboratories is expected to report on Jan 28, 2027, before the market opens (84 days away). Analysts expect earnings of $1.64 per share on revenue of $13.22B. Abbott Laboratories beat the earnings estimate in 3 of its last 8 reports, moving 6% on average across the report.
What is Abbott Laboratories’s 52-week high and low?
Abbott Laboratories’s 52-week high is $132.03 and its 52-week low is $81.97; it closed at $115.51 on Nov 4, 2026, −6.7% over the past year. Over the last five years the shares peaked at $142.60 on Dec 27, 2021.
Is Abbott Laboratories stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (trend, fair value, smart money, earnings risk and seasonality) and 1 as a headwind (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Abbott Laboratories the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.